Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in Malignant Pleural Mesothelioma.

cMYC lncRNA mesothelioma protein synthesis translation

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 05 12 2023
revised: 26 04 2024
accepted: 06 05 2024
medline: 11 5 2024
pubmed: 11 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

Malignant pleural mesothelioma is a rare and lethal cancer caused by exposure to asbestos. The highly inflammatory environment caused by fibers accumulation forces cells to undergo profound adaptation to gain survival advantages. Prioritizing the synthesis of essential transcripts is an efficient mechanism coordinated by multiple molecules, including long non-coding RNAs. Enhancing the knowledge about these mechanisms is an essential weapon in combating mesothelioma. Linc00941 correlates to bad prognosis in various cancers, but it is reported to partake in distinct and apparently irreconcilable processes. In this work, we report that linc00941 supports the survival and aggressiveness of mesothelioma cells by influencing protein synthesis and ribosome biogenesis. Linc00941 binds to the translation initiation factor eIF4G, promoting the selective protein synthesis of cMYC, which, in turn, enhances the expression of key genes involved in translation. We analyzed a retrospective cohort of 97 mesothelioma patients' samples from our institution, revealing that linc00941 expression strongly correlates with reduced survival probability. This discovery clarifies linc00941's role in mesothelioma and proposes a unified mechanism of action for this lncRNA involving the selective translation of essential oncogenes, reconciling the discrepancies about its function.

Identifiants

pubmed: 38729555
pii: S0304-3835(24)00343-4
doi: 10.1016/j.canlet.2024.216950
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

216950

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Auteurs

Mila Gugnoni (M)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy. Electronic address: mila.gugnoni@ausl.re.it.

Eugenia Lorenzini (E)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy.

Federica Torricelli (F)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy.

Benedetta Donati (B)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy.

Veronica Manicardi (V)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy.

Emanuele Vitale (E)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Italy.

Silvia Muccioli (S)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Italy.

Simonetta Piana (S)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Italy.

Filippo Lococo (F)

Università Cattolica del Sacro Cuore, Rome, Italy; UOC Chirurgia Toracica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Raffaella Zamponi (R)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy.

Paolo Gandellini (P)

Department of Biosciences, University of Milan, 20133 Milan, Italy.

Alessia Ciarrocchi (A)

Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Italy. Electronic address: alessia.ciarrocchi@ausl.re.it.

Classifications MeSH